Christopher A. Fausel

Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study

Costantine Albany, Mary J. Brames, Christopher A. Fausel et al. · Journal of Clinical Oncology · 2012 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01-21

Attaya Suvannasankha, Christopher A. Fausel, Beth E. Juliar et al. · The Oncologist · 2007 · 51 citations

Medicine, Pharmacology, Pharmacotherapy +17

Prophylaxis with Sirolimus and Tacrolimus ± Antithymocyte Globulin Reduces the Risk of Acute Graft-versus-Host Disease without an Overall Survival Benefit Following Allogeneic Stem Cell Transplantation

Lindsay Rosenbeck, Patrick J. Kiel, Iftekhar Kalsekar et al. · Biology of Blood and Marrow Transplantation · 2010 · 32 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia

R.P. Nelson, Menggang Yu, Jennifer E. Schwartz et al. · Bone Marrow Transplantation · 2010 · 17 citations

Medicine, Oncology, Pharmacology +17

Observations of Second Primary Malignancy in Patients With Multiple Myeloma

Anne Ormerod, Christopher A. Fausel, Rafat Abonour et al. · Clinical Lymphoma Myeloma & Leukemia · 2011 · 17 citations

Medicine, Hematology, Oncology +14